SGLT-2 inhibitors and their potential in the treatment of diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 453-467

  Rosenwasser, Rebecca F ^a   Sultan, Senan ^b   Sutton, David ^b   Choksi, Rushab ^a   Epstein, Benjamin J ^c  

^a East Coast Institute for Research   (United States)

^b Northeast Florida Endocrine and Diabetes Associates   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Canagliflozin; Dapagliflozin; Diabetes; Empagliflozin; Sodium glucose transporter 2

Indexed keywords

ANTIDIABETIC AGENT; BI 44847; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; GSK 1614235; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; ISIS 388626; LINAGLIPTIN; LUSEOGLIFLOZIN; LX 4211; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; TS 071; UNCLASSIFIED DRUG; URIC ACID;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BLOOD PRESSURE MEASUREMENT; BONE DENSITY; BREAST CANCER; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FAMILIAL RENAL GLUCOSURIA; FEMALE GENITAL TRACT INFECTION; FOOD AND DRUG ADMINISTRATION; FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE GALACTOSE MALABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE REABSORPTION; GLUCOSURIA; GLYCEMIC CONTROL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID ANALYSIS; LIVER FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECOMMENDED DRUG DOSE; RENAL DIABETES; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VULVITIS; VULVOVAGINAL MYCOTIC INFECTION; VULVOVAGINITIS; WEIGHT REDUCTION;

EID: 84888346204     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S34416     Document Type: Review

References (84)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http: //www. cdc. gov/diabetes/pubs/pdf/ndfs_2011. pdf. Accessed December 27, 2012.
2. Centers for Disease Control and Prevention. Diabetes Report Card 2012. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2012. Available from: http: //www. cdc. gov/diabetes/pubs/pdf/DiabetesReportCard. pdf. Accessed December 27, 2012.
3. Basile J. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Postgrad Med. 2011; 123(4): 38-45.
4. Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diabetes Educ. 2010; 36 Suppl 3: 44S-72S.
5. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010. Diabetes Care. Epub February 15, 2013.
6. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009; 53(5): 875-883.
7. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009; 11(2): 79-88.
8. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012; 9(2): 117-123.
9. Vallaeys L, Van Biervliet S, De Bruyn G, et al. Congenital glucose-galactose malabsorption: a novel deletion within the SLC5A1 gene. Eur J Pediatr. 2013; 172(3): 409-411.
10. Francis J, Geller D. Glucosuria, Primary Renal. In: Florian Lang, editor. Encyclopedia of Molecular Mechanisms of Disease. New York: Springer-Verlag GmbH Berlin Heidelberg; 2009: 719-721.
11. Canagliflozin [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2013.
12. Song J. Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus. Formulary [serial on the Internet]. Oct 2011; 46: 412-431. http: //formularyjournal. modernmedicine. com/formulary-journal/news/clinical/clinical-pharmacology/dapagliflozin-emerging-treatment-option-type-2. Accessed May 21, 2013.
13. Burki T. FDA rejects novel diabetes drug over safety fears. Lancet. 2012; 379(9815): 507.
14. Ptaszynska A, Johnsson K, Apanovitch A, Sugg J, Parikh S, List J. Safety of Dapagliflozin in Clinical Trials for T2DM. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
15. Leiter L, Cefalu W, de Bruin T, Gause-Nilsson I, Sugg J, Parikh S. Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients with a History of Cardiovascular Disease. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
16. Dapagliflozin [summary of product characteristics]. Middlesex, United Kingdom: Bristol-Myers Squibb/AstraZeneca; 2013.
17. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32(4): 650-657.
18. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010; 33(10): 2217-2224.
19. Woo V, Tang W, Salsali A, List J. Long-term Efficacy of Dapagliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus. Presented at IDF World Diabetes Congress; December 4-8, 2011; Dubai, United Arab Emirates.
20. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-tern Efficacy and Safety of Dapagliflozin vs Glipizide Added to Metformin in Patients with Inadequately Controlled T2DM. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
21. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term Efficacy and Safety of Add-on Dapagliflozin vs Add-on Glipizide in Patients with T2DM Inadequately Controlled with Metformin: 2-year Results. Presented at 71st American Diabetes Association Scientific Sessions; June 24-28, 2011; San Diego, CA, USA.
22. Del Prato S, Nauck M, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term Efficacy and Safety of Add-on Dapagliflozin vs Add-on Glipizide in Patients with T2DM Inadequately Controlled with Metformin: 2-year Results. Presented at 47th EASD Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
23. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9): 2015-2022.
24. Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J. Long-term Efficacy of Dapagliflozin as Add-on to Metformin in T2DM Inadequately Controlled with Metformin Alone. Presented at 71st American Diabetes Association Scientific Sessions; June 24-28, 2011; San Diego, CA, USA.
25. Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J. Long-term Efficacy of Dapagliflozin as Add-on to Metformin in T2DM Inadequately Controlled with Metformin Alone. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
26. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13(10): 928-938.
27. Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin Added-On to Pioglitazone Reduces HbA1c and Mitigates Weight Gain with low Incidence of Hypoglycemia in Type 2 Diabetes. Presented at 71st American Diabetes Association Scientific Sessions; June 24-28, 2011; San Diego, CA, USA.
28. Vico M, Wei L, Salsali A, List J, Rosenstock J. Dapagliflozin Added-on to Pioglitazone is Effective in Improving Glycaemic Control and Attenuates Weight Gain Without Increasing Hypoglycemia in Patients with Type 2 Diabetes. Presented at 47th EASD Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
29. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35(7): 1473-1478.
30. Wilding J, Woo V, Soler N, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156(6): 405-415.
31. Woo V, Wilding J, Rohwedder K, Sugg J, Parikh S. Long-term Effectiveness of Dapagliflozin Over 104 Weeks in Patients with T2DM Inadequately Controlled with Insulin. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
32. Wilding J, Woo V, Rohwedder K, Sugg J, Parikh S. Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients with Type 2 Diabetes Poorly Controlled with Insulin. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
33. FDA. gov [homepage on the Internet]. Silver Spring, MD: US Food and Drug Administration. Available from: http: //www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848. htm. Accessed May 21, 2013.
34. Jnj. com [homepage on the Internet]. Raritan, NJ: Johnson and Johnson; Available from: http: //www. jnj. com/connect/news/all/fda-advisory-committee-recommends-approval-of-canagliflozin-for-treatment-of-adults-with-type-2-diabetes. Accessed May 21, 2013.
35. Stenlof K, Cefalu W, Tong C, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control in subjects with type 2 diabetes inadequately controlled with diet and exercise. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
36. Polidori D, Law G, Alba M, Ferrannini E. Treatment with Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, for 26 Weeks Improves Indices of Beta-cell Function. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
37. Cefalu W, Leiter L, Niskanen L, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared With Glimepiride in Patients with Type 2 Diabetes on Background Metformin. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
38. Niskanen L, Cefalu W, Leiter L, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
39. Niskanen L, Cefalu W, Leiter L, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
40. Wilding J, Mathieu C, Vercruysse F, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
41. Wilding J, Mathieu C, Deng L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea. Presented at 48th EASD Annual Meeting; October 1-5, 20125; Berlin, Germany.
42. Gross J, Schernthaner G, Fu M, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared with Sitagliptin in Patients with Type 2 Diabetes On Metformin Plus Sulfonylurea. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
43. Schernthaner G, Gross J, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulphonylurea. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
44. Polidori D, Vercruysse F, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves indices of beta cell function in patients with type 2 diabetes on metformin plus sulphonylurea. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
45. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
46. Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy with or without oral agents in type 2 diabetes. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
47. Newsroom. lilly. com [homepage on the Internet]. Indianapolis, IN: Eli Lilly and Company; Boehringer Ingelheim. Available from: http: //newsroom. lilly. com/releasedetail. cfm?releaseidm731715. Accessed May 21, 2013.
48. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Worle H. The Potent and Highly Selective Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor BI 10773 is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM). Presented at 46th EASD Annual Meeting; September 20-24, 2010; Stockholm, Sweden.
49. Woerle H, Ferrannini E, Berk A, Hantel S, Pinnetti S, Broedl U. Safety and Efficacy of Empagliflozin as Monotherapy or Add-On to Metformin in a 78-Week Open-Label Extension Study in Patients with Type 2 Diabetes. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
50. Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle H. Efficacy and Safety of BI 10773 (Empagliflozin), a New Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, in Type 2 Diabetes Inadequately Controlled on Metformin. Presented at 71st American Diabetes Association Scientific Sessions; June 24-28, 2011; San Diego, CA, USA.
51. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther. Jul 2013; 139(1): 51-59.
52. Kashiwagi A, Shiga T, Akiyama N, et al. Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
53. Freiman J, Ye G, Ogbaa I, et al. LX4211, a dual SGLT1/SGLT2 inhibitor shows a favourable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus patients and healthy subjects. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
54. Lexicon-genetics. com [homepage on the Internet]. The Woodlands, TX: Lexicon Pharmaceuticals. Available from: http: //www. lexicon-genetics. com/pipeline/lx4211. html. Accessed May 21, 2013.
55. Chugai-pharm. com [homepage on the Internet]. Chuo-ku, Tokyo: Chugai Pharma USA. Available from: http: //www. chugai-pharm. co. jp/hc/ss/english/ir/reports_downloads/pipeline. html. Accessed May 21, 2013.
56. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
57. Taisho-holdings. co. jp/en [homepage on the Internet]. Toshima-ku, Tokyo: Taisho Pharmaceutical. Available from: http: //www. taisho-holdings. co. jp/en/release/2012/2012113001-e. pdf. Accessed May 21, 2013.
58. Pfizer. newshq. businesswire. com [homepage on the Internet]. New York, NY: Pfizer. Available from: http: //pfizer. newshq. businesswire. com/press-release/merck-co-inc-and-pfizer-enter-worldwide-collaboration-agreement-develop-and-commercial. Accessed May 21, 2013.
59. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. Jul 2010; 9(7): 551-559.
60. Bailey C, Iqbal N, T'joen C, List J. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012; 14(10): 951-959.
61. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99(11): 759-766.
62. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12(6): 510-516.
63. Toubro S, Cefalu W, Xie J, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
64. Toubro S, Cefalu W, Xie J, et al. Canagliflozin reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
65. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3): 1020-1031.
66. Hach T, Lambers Heerspink H, Pfarr E, Lund S, Ley L, Broedl U. The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Empagliflozin Lowers Blood Pressure Independent of Weight or HbA1c Changes [poster 65]. Proceedings of the 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
67. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012; 12(3): 230-238.
68. Damkjær M, Isaksson GL, Stubbe J, Jensen BL, Assersen K, Bie P. Renal renin secretion as regulator of body fluid homeostasis. Pflugers Arch. 2013; 465(1): 153-165.
69. Thomson S, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012; 302(1): R75-R83.
70. Woo V, Hardy E, Ptaszynska A, Parikh S. Effects of the SGLT2 Inhibitor Dapagliflozin Beyond Glucose Reduction in Patients with Type 2 Diabetes mellitus. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
71. Hardy E, Rohwedder K, Hruba V, et al. Dapagliflozin, an AGLT2 Inhibitor, reduces Serum Levels of Uric Acid in patients with Type 2 Diabetes. Presented at 71st American Diabetes Association Scientific Sessions; June 24-28, 2011; San Diego, CA, USA.
72. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am. 2006; 32(2): 313-331, vi.
73. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. Epub December 4, 2012.
74. Yale JF, Bakris G, Xi L, Figueroa K, Wajs E, Usiskin K, et al. Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
75. Bakris G, Yale JF, Xi L, et al. Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Moderate Renal Impairment. Presented at ASN Kidney Week; October 30-November 4, 2012; San Diego, CA, USA.
76. Yale JF, Bakris G, Wajs E, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control and is well tolerated in type 2 diabetes subjects with moderate renal impairment. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
77. Woo V, Davies M, de Zeeuw D, et al. Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment. Presented at 4th World Congress on Controversies in Diabetes, Obesity, and Hypertension (CODHy); November 8-11, 2012; Barcelona, Spain.
78. Kohan D, Fioretto P, List J, Tang W. Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment. Presented at ASN Kidney Week; November 10-13, 2011; Philadelphia, PA, USA.
79. Ptaszynska A, Chalamandaris AG, Sugg J, Johnsson K, Parikh S, List J. Effect of Dapagliflozin on Renal Function [poster 1098-P]. Proceedings of the 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.
80. Kasichayanula S, Liu X, Pe Benito M, LaCreta F, Boulton D. Influence of Renal Function on Dapagliflozin Pharmacodynamics in Patients with Type 2 Diabetes Mellitus. Presented at ASN Kidney Week; November 10-13, 2011; Philadelphia, PA, USA.
81. van Lierop AH, Hamdy NA, van der Meer RW, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012; 166(4): 711-716.
82. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K, Meininger G. Efficacy and safety of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus. Presented at 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.
83. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32(3): 187-202.
84. Cefalu W, Leiter L, de Bruin T, Gause-Nilsson I, Sugg J, Parikh S. Dapagliflozin Treatment for Type 2 Diabetes Mellitus patietns with Comorbid Cardiovascular Disease and Hypertension. Presented at 72nd American Diabetes Association Scientific Sessions; June 8-12, 2012; Philadelphia, PA, USA.